Meeting
2020 ASCO Virtual Scientific Program
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
Authors
Hareth Nahi
Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
Hareth Nahi , Saad Zafar Usmani , Maria-Victoria Mateos , Niels W.C.J. van de Donk , Philippe Moreau , Albert Oriol , Torben Plesner , Shiyi Yang , Peter Hellemans , Brenda J. Tromp , Man (Melody) Luo , Donna Zemlickis , Andrew Farnsworth , Ajai Chari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02519452
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8537)
DOI
10.1200/JCO.2020.38.15_suppl.8537
Abstract #
8537
Poster Bd #
437
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
First Author: Saad Zafar Usmani
Poster
2018 ASCO Annual Meeting
Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
First Author: Ajai Chari
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld
Poster
2018 ASCO Annual Meeting
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
First Author: S.Vincent Rajkumar